论文部分内容阅读
目的:观察后程加速超分割放射治疗早期鼻咽癌的临床疗效、毒副反应及后遗症。方法:将108例I～II期鼻咽癌患者随机分为常规分割放疗组常规组和后程加速超分割放疗组后超组,每组54例。常规组照射2Gy/次,5次/周总量为70Gy/7周。后超组前3.5周照射同常规组,然后开始1.5Gy/次,2次/日,间隔6h,总量为69Gy/6周。结果:鼻咽部肿瘤消退率:常规组为70.97%22/31,后超组为89.47%(34/38),但两组差别无显著性意义(P=0.05);颈部淋巴结完全消退率:常规组为86.67%26/30,后超组为90.91%30/33,两组差别无显著性意义(P>0.05);两组1、2、3年生存率分别为96.12%、80.97%、78.55%和98.13%、93.95%、90.87%P=0.06,无明显的统计学差异;两组放疗毒副反应及后遗症也无显著性差别(P>0.05)。结论:I～II期鼻咽癌后程加速超分割放疗疗效未见优于常规分割放疗,但未加重放疗毒副反应及增加放疗后遗症,有必要扩大病例并作长期随访研究。
Objective: To observe the clinical effect, side effects and sequelae of late course accelerated hyperfractionation radiotherapy for early stage nasopharyngeal carcinoma. Methods: One hundred and eighty patients with stage I-II nasopharyngeal carcinoma were randomly divided into conventional radiotherapy group and conventional radiotherapy group, followed by accelerated hyperfraction radiotherapy group. Conventional group irradiation 2Gy / times, 5 times / weekly total amount of 70Gy / 7 weeks. After 3.5 weeks before the super-group irradiation with the conventional group, and then start 1.5Gy / time, 2 times / day, 6h intervals, the total amount of 69Gy / 6 weeks. Results: The rate of nasopharyngeal tumor regression was 70.97% 22 / 31 in the conventional group and 89.47% (34/38) in the latter group, but there was no significant difference between the two groups (P = 0.05). The complete cervical lymph node The regression rate was 86.67% 26 / 30 in the conventional group and 90.91% 30 / 33 in the post-super-group, with no significant difference between the two groups (P> 0.05). The 1, 2, 3-year survival rates (96.12%, 80.97%, 78.55%, 98.13%, 93.95%, 90.87% P = 0.06,, respectively). There was no significant difference between the two groups in radiotherapy side effects and sequelae (P> 0.05). Conclusion: It is necessary to enlarge the cases and make long-term follow-up study on the accelerated course of accelerated hyperfraction radiotherapy for stage I ~ II nasopharyngeal carcinoma, which is not superior to conventional radiotherapy.